Eslicarbazepine Acetate Well Tolerated, Effective in Post-Stroke Epilepsy
Eslicarbazepine acetate is well tolerated and may be effective for treating patients with post-stroke epilepsy.
Eslicarbazepine acetate is well tolerated and may be effective for treating patients with post-stroke epilepsy.
Adjunctive brivaracetam may provide long term effectiveness in adults who have not seen optimal results with other common treatments.
Bioequivalent generic formulations of 2 antiepileptic medications were comparable to brand name treatments for new-onset epilepsy.
Children with Dravet syndrome receiving fenfluramine experienced improvements in emotional regulation, behavioral regulation, and planning and organization abilities.
Researchers aimed to identify risk factors associated with a psychiatric event following a first prescription for levetiracetam.
Patients taking an active treatment regimen consisting of SSRIs, TCAs, or antipsychotic medications are less likely to experience a seizure in the epilepsy monitoring unit.
The classic ketogenic diet may not have a significant impact on preventing shttp://cms.haymarketmedia.com/Images/find.gifeizure occurrence in patients with infantile spasms of unknown etiology.
Individual treatment-emergent adverse events (TEAE) did not increase with higher modal daily dose of eslicarbazepine acetate in pediatric patients with focal seizures.
Perampanel at a median maximum dose of 6 mg (1 to 20 mg) is associated with good long-term treatment retention and sustained efficacy.
Investigators aimed to determine whether utilization of enzyme-inducing antiepileptic drugs increases vitamin D requirements.